Harrison G. Zhang

Harrison G. Zhang

Auto-generated profile, based on publicly available information

Harrison G. Zhang

Department of Biomedical Data Science, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HZHarrison G. Zhang
Harrison G. Zhang
JHJacqueline P. Honerlaw
Jacqueline P. Honerlaw
MMMonika Maripuri
Monika Maripuri
MSMalarkodi Jebathilagam Samayamuthu
Malarkodi Jebathilagam Samayamuthu
BBBrendin R. Beaulieu-Jones
Brendin R. Beaulieu-Jones
GBGabriel A. Brat
Gabriel A. Brat

11 October 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
GWGriffin M. Weber
Griffin M. Weber
HZHarrison G Zhang
Harrison G Zhang
SLSehi L'Yi
Sehi L'Yi
CBClara-Lea Bonzel
Clara-Lea Bonzel
Chuan HongChuan Hong
Chuan Hong
GBGabriel A Brat
Gabriel A Brat
Background: Many countries have experienced 2 predominant waves of COVID-19–related hospitalizations. Comparing the clinical trajectories of patients hospitalized in separate waves of the pandemic enables further understanding of the evolving epidemiology, pathophysiology, and health care dynamics of the COVID-19 pandemic. Objective: In this retrospective cohort study, we analyzed electronic health record (EHR) data from patients with SARS-CoV-2 infections hospitalized in participating health care systems representing 315 hospitals across 6 countries. We compared hospitalization rates, severe COVID-19 risk, and mean laboratory values between patients hospitalized during the first and second waves of the pandemic. Methods: Using a federated approach, each participating health care system extracted patient-level clinical data on their first and second wave cohorts and submitted aggregated data to the central site. Data quality control steps were adopted at the central site to correct for implausible values and harmonize units. Statistical analyses were performed by computing individual health care system effect sizes and synthesizing these using random effect meta-analyses to account for heterogeneity. We focused the laboratory analysis on C-reactive protein (CRP), ferritin, fibrinogen, procalcitonin, D-dimer, and creatinine based on their reported associations with severe COVID-19. Results: Data were available for 79,613 patients, of which 32,467 were hospitalized in the first wave and 47,146 in the second wave. The prevalence of male patients and patients aged 50 to 69 years decreased significantly between the first and second waves. Patients hospitalized in the second wave had a 9.9% reduction in the risk of severe COVID-19 compared to patients hospitalized in the first wave (95% CI 8.5%-11.3%). Demographic subgroup analyses indicated that patients aged 26 to 49 years and 50 to 69 years; male and female patients; and black patients had significantly lower risk for severe disease in the second wave than in the first wave. At admission, the mean values of CRP were significantly lower in the second wave than in the first wave. On the seventh hospital day, the mean values of CRP, ferritin, fibrinogen, and procalcitonin were significantly lower in the second wave than in the first wave. In general, countries exhibited variable changes in laboratory testing rates from the first to the second wave. At admission, there was a significantly higher testing rate for D-dimer in France, Germany, and Spain. Conclusions: Patients hospitalized in the second wave were at significantly lower risk for severe COVID-19. This corresponded to mean laboratory values in the second wave that were more likely to be in typical physiological ranges on the seventh hospital day compared to the first wave. Our federated approach demonstrated the feasibility and power of harmonizing heterogeneous EHR data from multiple international health care systems to rapidly conduct large-scale studies to characterize how COVID-19 clinical trajectories evolve.

3 May 2024 in Online Journal of Public Health Informatics
Verified
Journal Article
Open access
MMMonika Maripuri
Monika Maripuri
ADAndrew Dey
Andrew Dey
JHJacqueline Honerlaw
Jacqueline Honerlaw
Chuan HongChuan Hong
Chuan Hong
YHYuk-Lam Ho
Yuk-Lam Ho
KCKelly Cho
Kelly Cho
Background: Post–COVID-19 condition (colloquially known as “long COVID-19”) characterized as postacute sequelae of SARS-CoV-2 has no universal clinical case definition. Recent efforts have focused on understanding long COVID-19 symptoms, and electronic health record (EHR) data provide a unique resource for understanding this condition. The introduction of the International Classification of Diseases, Tenth Revision (ICD-10) code U09.9 for “Post COVID-19 condition, unspecified” to identify patients with long COVID-19 has provided a method of evaluating this condition in EHRs; however, the accuracy of this code is unclear. Objective: This study aimed to characterize the utility and accuracy of the U09.9 code across 3 health care systems—the Veterans Health Administration, the Beth Israel Deaconess Medical Center, and the University of Pittsburgh Medical Center—against patients identified with long COVID-19 via a chart review by operationalizing the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) definitions. Methods: Patients who were COVID-19 positive with either a U07.1 ICD-10 code or positive polymerase chain reaction test within these health care systems were identified for chart review. Among this cohort, we sampled patients based on two approaches: (1) with a U09.9 code and (2) without a U09.9 code but with a new onset long COVID-19–related ICD-10 code, which allows us to assess the sensitivity of the U09.9 code. To operationalize the long COVID-19 definition based on health agency guidelines, symptoms were grouped into a “core” cluster of 11 commonly reported symptoms among patients with long COVID-19 and an extended cluster that captured all other symptoms by disease domain. Patients having ≥2 symptoms persisting for ≥60 days that were new onset after their COVID-19 infection, with ≥1 symptom in the core cluster, were labeled as having long COVID-19 per chart review. The code’s performance was compared across 3 health care systems and across different time periods of the pandemic. Results: Overall, 900 patient charts were reviewed across 3 health care systems. The prevalence of long COVID-19 among the cohort with the U09.9 ICD-10 code based on the operationalized WHO definition was between 23.2% and 62.4% across these health care systems. We also evaluated a less stringent version of the WHO definition and the CDC definition and observed an increase in the prevalence of long COVID-19 at all 3 health care systems. Conclusions: This is one of the first studies to evaluate the U09.9 code against a clinical case definition for long COVID-19, as well as the first to apply this definition to EHR data using a chart review approach on a nationwide cohort across multiple health care systems. This chart review approach can be implemented at other EHR systems to further evaluate the utility and performance of the U09.9 code.

28 April 2023 in EBioMedicine
Verified
Journal Article
Open access
HZHarrison G. Zhang
Harrison G. Zhang
GMGreg McDermott
Greg McDermott
TSThany Seyok
Thany Seyok
SHSicong Huang
Sicong Huang
KDKumar Dahal
Kumar Dahal
KLKatherine P. Liao
Katherine P. Liao
Rheumatoid arthritis (RA) shares genetic variants with other autoimmune conditions, but existing studies test the association between RA variants with a pre-defined set of phenotypes. The objective of this study was to perform a large-scale, systemic screen to determine phenotypes that share genetic architecture with RA to inform our understanding of shared pathways. In the UK Biobank (UKB), we constructed RA genetic risk scores (GRS) incorporating human leukocyte antigen (HLA) and non-HLA risk alleles. Phenotypes were defined using groupings of International Classification of Diseases (ICD) codes. Patients with an RA code were excluded to mitigate the possibility of associations being driven by the diagnosis or management of RA. We performed a phenome-wide association study, testing the association between the RA GRS with phenotypes using multivariate generalized estimating equations that adjusted for age, sex, and first five principal components. Statistical significance was defined using Bonferroni correction. Results were replicated in an independent cohort and replicated phenotypes were validated using medical record review of patients. We studied n = 316,166 subjects from UKB without evidence of RA and screened for association between the RA GRS and n = 1317 phenotypes. In the UKB, 20 phenotypes were significantly associated with the RA GRS, of which 13 (65%) were immune mediated conditions including polymyalgia rheumatica, granulomatosis with polyangiitis (GPA), type 1 diabetes, and multiple sclerosis. We further identified a novel association in Celiac disease where the HLA and non-HLA alleles had strong associations in opposite directions. Strikingly, we observed that the non-HLA GRS was exclusively associated with greater risk of the validated conditions, suggesting shared underlying pathways outside the HLA region. This study replicated and identified novel autoimmune phenotypes verified by medical record review that share immune pathways with RA and may inform opportunities for shared treatment targets, as well as risk assessment for conditions with a paucity of genomic data, such as GPA. This research was funded by the US National Institutes of Health (P30AR072577, R21AR078339, R35GM142879, T32AR007530) and the Harold and DuVal Bowen Fund.

4 July 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
CHChuan Hong
Chuan Hong
JWJun Wen
Jun Wen
HZHarrison G. Zhang
Harrison G. Zhang
VPVidul Ayakulangara Panickan
Vidul Ayakulangara Panickan
DYDoris Y. Yang
Doris Y. Yang
TCTianxi Cai
Tianxi Cai
Long COVID poses a significant disease burden globally, but its heterogeneous presentation and unreliable coding practices render it difficult to study. Developing efficient phenotyping algorithms is crucial to enabling risk prediction and effective management of Long COVID. We introduce the LAbel-efficienT Long COVID pHenotyping (LATCH) algorithm, which synthesizes a small number of gold-standard labels and a large, unlabeled dataset with many electronic health record (EHR) features. Both internal validation and external validation demonstrated the superior performance of LATCH over methods using the U09.9 Long COVID EHR code alone. Our downstream analysis revealed a pattern of elevated healthcare utilization due to Long COVID, peaking at and continuing beyond the fourth month following COVID infection. LATCH enhances the classification of Long COVID by fully utilizing both labeled and unlabeled data, providing vital insights into healthcare utilization trends, informing clinical and public health responses to the enduring consequences of COVID-19.

22 October 2026 in Science
Verified
Journal Article
Closed access
HZHarrison G. Zhang
Harrison G. Zhang
PEPeter Eckmann
Peter Eckmann
JMJiacheng Miao
Jiacheng Miao
AMAndrew B. Mahon
Andrew B. Mahon
JZJames Y Zou
James Y Zou
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development. We demonstrate its utility at three drug-development decision points. First, more than 37,000 agents annotated outcomes from 55,984 trials and found that drugs targeting cell type–specific genes were 48% more likely to reach market with 32% fewer adverse events. Second, it integrated multimodal evidence to propose a therapeutic strategy in lung cancer. Third, it analyzed a terminated ulcerative colitis trial and inferred potential mechanisms of failure. These results demonstrate that human-guided multi-agent systems can conduct transparent, multiscale analyses to inform therapeutic-development decisions.